DANIEL KIM: Open Payments
NPI 1275813370 · SAN BERNARDINO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$914 in 36 payments from 12 companies in 2025. Trend: 2023 $2,321 · 2024 $815 · 2025 $914
Food & beverage: $914
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $268 |
| Lilly USA, LLC | 3 | $157 |
| Incyte Corporation | 4 | $103 |
| Novartis Pharmaceuticals Corporation | 3 | $81 |
| GENZYME CORPORATION | 2 | $65 |
| Arcutis Biotherapeutics, Inc. | 4 | $60 |
| Organon LLC | 2 | $57 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| UCB, Inc. | 1 | $28 |
Products named: SKYRIZI, RINVOQ, EBGLYSS, OPZELURA, DUPIXENT, Rhapsido, Zoryve, VTAMA.
Industry payments across CA — which companies pay providers there.
